Pathologically documented, locally advanced or metastatic malignancy with KRAS G12V mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic.

Part 1: Advanced solid tumors with at least one prior systemic therapy.

Evaluable and measurable disease per RECIST v1.1.

Part 2 and 3: Measurable disease per RECIST v1.1.

QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

What this study is about